TNFα up-regulates COX-2 in chronic progressive nephropathy through nuclear accumulation of RelB and NF-κB2

References

• Ackerman WET, Summerfield TL, Vandre DD, et al. (2008). Nuclear factor-kappa B regulates inducible prostaglandin E synthase expression in human amnion mesenchymal cells. Biol Reprod, 78:68–76
   PubMed Web of Science ®Google Scholar
• Al-Malki AL, Sayed AA, El Rabey HA. (2013). Proanthocyanidin attenuation of oxidative stress and NF- kappa B protects apolipoprotein E-deficient mice against diabetic nephropathy. Evid Based Complement Alternat Med, 2013:769409
   PubMedGoogle Scholar
• Becker JC, Domschke W, Pohle T. (2004). Current approaches to prevent NSAID-induced gastropathy – COX selectivity and beyond. Br J Clin Pharmacol, 58:587–600
   PubMed Web of Science ®Google Scholar
• Brantley DM, Chen CL, Muraoka RS, et al. (2001). Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in mouse mammary epithelium. Mol Biol Cell, 12:1445–55
   PubMed Web of Science ®Google Scholar
• Fujihara CK, Antunes GR, Mattar AL, et al. (2003). Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney. Kidney Int, 64:2172–81
   PubMed Web of Science ®Google Scholar
• Guo Y, Liu Y, Wang Y. (2015). Beneficial effect of lycopene on anti-diabetic nephropathy through diminishing inflammatory response and oxidative stress. Food Funct, 6:1150–6
   PubMed Web of Science ®Google Scholar
• Hayden MS, Ghosh S. (2008). Shared principles in NF-kappaB signaling. Cell, 132:344–62
   PubMed Web of Science ®Google Scholar
• Hehlgans T, Pfeffer K. (2005). The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: Players, rules and the games. Immunology, 115:1–20
   PubMed Web of Science ®Google Scholar
• Kaltschmidt B, Linker RA, Deng J, et al. (2002). Cyclooxygenase-2 is a neuronal target gene of NF-kappaB. BMC Mol Biol, 3:16
   PubMed Web of Science ®Google Scholar
• Kitahara M, Eitner F, Ostendorf T, et al. (2002). Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis. J Am Soc Nephrol, 13:1261–70
   PubMed Web of Science ®Google Scholar
• Maeda S. (2008). Do inflammatory cytokine genes confer susceptibility to diabetic nephropathy? Kidney Int, 74:413–15
   PubMed Web of Science ®Google Scholar
• Morham SG, Langenbach R, Loftin CD, et al. (1995). Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell, 83:473–82
   PubMed Web of Science ®Google Scholar
• Muller CW, Rey FA, Sodeoka M, et al. (1995). Structure of the NF-kappa B p50 homodimer bound to DNA. Nature, 373:311–17
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalez JF, Mora-Fernandez C. (2008). The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol, 19:433–42
   PubMed Web of Science ®Google Scholar
• O’Connell MA, Cleere R, Long A, et al. (1995). Cellular proliferation and activation of NF kappa B are induced by autocrine production of tumor necrosis factor alpha in the human T lymphoma line HuT 78. J Biol Chem, 270:7399–404
   PubMed Web of Science ®Google Scholar
• Plumpe J, Malek NP, Bock CT, et al. (2000). NF-kappaB determines between apoptosis and proliferation in hepatocytes during liver regeneration. Am J Physiol Gastrointest Liver Physiol, 278:G173–83
   PubMed Web of Science ®Google Scholar
• Qing G, Qu Z, Xiao G. (2005). Regulation of NF-kappa B2 p100 processing by its cis-acting domain. J Biol Chem, 280:18–27
   PubMed Web of Science ®Google Scholar
• Ricciotti E, FitzGerald GA. (2011). Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol, 31:986–1000
   PubMed Web of Science ®Google Scholar
• Sedger LM, McDermott MF. (2014). TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future. Cytokine Growth Factor Rev, 25:453–72
   PubMed Web of Science ®Google Scholar
• Sobolewski C, Cerella C, Dicato M, et al. (2010). The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol, 2010:215158
   PubMedGoogle Scholar
• Sun SC. (2011). Non-canonical NF-kappaB signaling pathway. Cell Res, 21:71–85
   PubMed Web of Science ®Google Scholar
• Suzuki S, Fukasawa H, Misaki T, et al. (2011). Up-regulation of Cks1 and Skp2 with TNFalpha/NF-kappaB signaling in chronic progressive nephropathy. Genes Cells, 16:1110–20
   PubMed Web of Science ®Google Scholar
• Vallabhapurapu S, Karin M. (2009). Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol, 27:693–733
   PubMed Web of Science ®Google Scholar
• Wang B, Parobchak N, Rosen T. (2012). RelB/NF-kappaB2 regulates corticotropin-releasing hormone in the human placenta. Mol Endocrinol, 26:1356–69
   PubMed Web of Science ®Google Scholar
• Wang JL, Cheng HF, Shappell S, et al. (2000). A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int, 57:2334–42
   PubMed Web of Science ®Google Scholar
• Williams CS, Mann M, Dubois RN. (1999). The role of cyclooxygenases in inflammation, cancer, and development. Oncogene, 18:7908–16
   PubMed Web of Science ®Google Scholar
• Xiao G, Fong A, Sun SC. (2004). Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J Biol Chem, 279:30099–105
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Arakawa T, Ueda N, et al. (1995). Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem, 270:31315–20
   PubMed Web of Science ®Google Scholar